Clinical Efficacy Evaluation of a Computer-aided Colonoscopy as Compared With the Standard Colonoscopy.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

1500 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-03-01

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Colonoscopy is clinically used as the gold standard for detection of colorectal cancer (CRC) and removal of adenomatous polyps of the colon and rectum. Evidence has shown that CRC could be prevented by colonoscopic removal of adenomatous polyps. Despite the success of colonoscopy in reducing cancer-related deaths, there exists a disappointing level of adenomas missed at colonoscopy. In recent years, emerging artificial intelligence (AI) and computer-aided detection (CADe) technology has been shown to improve ADR. Based on a meta-analysis, ADR was demonstrated to be significantly higher in the CADe groups than in the standard colonoscopy groups, representing a relative risk of 25.2%.

In this study, performance of colonoscopy with or without aid of CADe will be compared in terms of quality indicators. The adenoma detection rate (ADR), which is the proportion of average-risk patients undergoing screening colonoscopy in whom an adenoma is found, is regarded as a robust measure of colonoscopy performance quality that correlates with subsequent cancer risk. Thus, ADR is taken as the primary outcome of this study. The target population includes individuals who are undergoing screening, diagnostic, or surveillance colonoscopy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Longterm Effectiveness of Artificial Intelligence-assisted Colonoscopy on Adenoma Recurrence

NCT06251700

Screening Colonscopy

RECRUITING NA

Prospective Evalulation of Artificial Intelligence-assisted Monitoring of Effective Withdrawal Time Versus Standard Withdrawal Time on Adenoma Detected Per Colonoscopy

NCT06345105

Colon Polyp Colon Adenoma Artificial Intelligence

COMPLETED

Comparison of the Performance Between Conventional Colonoscopy and 3D Colonoscopy in Positive Fecal Immunochemical Test Group

NCT06678477

Adenoma Detection Rate Colonoscopy Three Dimensional +1 more

RECRUITING NA

Effect of Two Colonoscopy AI Systems for Colon Polyp Detection

NCT05089071

Adenoma Colonoscopy Sessile Serrated Adenoma

COMPLETED NA

Adenoma Detection Rate Using AI System in China

NCT03840590

Colorectal Neoplasms Colonic Polyp Adenoma

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This multiple-site study aims to evaluate whether a computer-aided detection (CADe) device can assist in adenoma detection rate (ADR) when compared with the current standard-of-care procedure. The subject CADe device used in this study contains an artificial intelligence/machine learning (AI/ML) advanced algorithm to aid the endoscopists in detection of colonic mucosal lesions and the detected polyps will be highlighted to the endoscopists during the real-time colonoscopy procedures. This study plans to enroll subjects aged ≥ 40 years and \< 80 years, who are scheduled for screening or diagnostic colonoscopy for colorectal cancer (CRC) or surveillance colonoscopy for post-polypectomy follow-up. After being evaluated with the inclusion and exclusion criteria, eligible subjects will be randomized in a 1:1 ratio to receive either the computer-aided colonoscopy (CC) or the standard colonoscopy(SC). Randomization will be stratified by gender, age, and colonoscopy indication (screening, diagnostic, or surveillance) of subjects. The resected polyps will be submitted for histologic examination by one expert pathologist at each site. If any uncertainty or doubt exists, an expert in gastrointestinal pathology will serve as the adjudicator to perform a second review and make the final decision. All of the pathologists (including the final adjudicator) who will perform the histopathologic examinations and produce the pathology assessment will be blinded to the assigned study arm of the specimens. The pathology reports of the subjects will be kept securely at each site as the source data.

The primary endpoint is the ADR of the CC as compared with that of the SC. The ADR is defined as the percentage of subjects undergoing a complete colonoscopy, who have at least one histologically confirmed adenoma detected and removed. In addition, the following secondary endpoints will also be evaluated, including: Polyp detection rate (PDR), Adenomas per colonoscopy (APC), Polyps per colonoscopy (PPC), Non-neoplastic polypectomy rate (NNPR), Non-neoplastic polypectomy (NNP), Sessile serrated lesions per colonoscopy (SPC), Advanced adenomas per colonoscopy (AAPC), and withdrawal time.

Signed written informed consent forms will be obtained from all participating subjects before enrollment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colon Adenoma Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SCREENING

Blinding Strategy

DOUBLE

Participants Outcome Assessors

The subject and the pathologist who performs the histopathological review will be blinded to the received procedure, while the operator for colonoscopy will not be blinded to the study arm assigned to the subject.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Computer-aided colonoscopy

The subject will receive the standard colonoscopy procedure simultaneously with a computer-aided detection (CADe) analysis software designed to automatically detect and highlight potential polyps on colonoscopy images in a real-time manner during colonoscopy procedures.

Group Type EXPERIMENTAL

"aetherAI" Computer-aided Polyp Detection (CADe) Systems for Colonoscopy

Intervention Type DEVICE

The investigational medical device is intended to automatically detect potential polyps via colonoscopy in real-time during colonoscopy examinations.

The subject device contains an artificial intelligence/machine learning (AI/ML) advanced algorithm to aid the endoscopists in detection of colonic mucosal lesions and the detected polyps will be highlighted to the endoscopists during the real-time colonoscopy procedures.

Standard colonoscopy

Intervention Type PROCEDURE

Standard colonoscopy procedure.

Standard colonoscopy

The subject will receive the standard colonoscopy procedure.

Group Type ACTIVE_COMPARATOR

Standard colonoscopy

Intervention Type PROCEDURE

Standard colonoscopy procedure.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

"aetherAI" Computer-aided Polyp Detection (CADe) Systems for Colonoscopy

The investigational medical device is intended to automatically detect potential polyps via colonoscopy in real-time during colonoscopy examinations.

The subject device contains an artificial intelligence/machine learning (AI/ML) advanced algorithm to aid the endoscopists in detection of colonic mucosal lesions and the detected polyps will be highlighted to the endoscopists during the real-time colonoscopy procedures.

Intervention Type DEVICE

Standard colonoscopy

Standard colonoscopy procedure.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects who have given signed informed consent form
* Informed consensus has been obtained that endoscopic resection should be performed if a lesion is found
* Subjects who are scheduled for screening or diagnostic colonoscopy for colorectal cancer (CRC) or surveillance colonoscopy for post-polypectomy follow-up

Exclusion Criteria

* Subjects with any of the following prior history or current conditions:

1. Contraindications to colonoscopy
2. Inflammatory bowel disease (IBD)
3. Colorectal cancer (CRC)
4. Familial adenomatous polyposis (FAP)
5. Colonic stenosis
6. Severe organ failure (cirrhosis of Child C, heart failure of ACC / AHA stage D)
7. Active gastrointestinal (GI) Bleeding
8. Pregnancy
9. Prior colorectal surgery, including colonic or rectal resection (except for appendectomy, surgery on the anus, and polypectomy)
10. Undergo colonoscopy within 3 years
* Subjects with any of the following conditions per the investigator's judgement:

1. High suspicion of IBD, CRC, and FAP.
2. High risk of bleeding after endoscopic treatment, and difficult management of anticoagulation or antiplatelet medication.

Minimum Eligible Age

40 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes